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Significant original research was reported at the American
College of Cardiology 2003 National Meeting in the field of
cardiac arrhythmias and implantable devices.
Cardiac resynchronization therapy (CRT) is still a topic
of great interest and rapid evolution. The initial results of
the Comparison of Medical Therapy, Pacing, and Defibril-
lation in Chronic Heart Failure (COMPANION) trial were
presented. This was the first CRT trial designed to assess
mortality. Patients were randomly assigned to optimized
medical therapy, biventricular pacing, or biventricular pac-
ing with implantable cardioverter-defibrillator (ICD) capa-
bility. The lowest mortality was observed in the group with
CRT and ICD (p  0.002). It also was noted that the
difference in response between patients with ischemic car-
diomyopathy and those with dilated cardiomyopathy was
not significant.
A question often asked about CRT is whether paced
patients who have an underlying intrinsic rhythm with a
narrow QRS interval receive benefit from an upgrade to
CRT. Oezatalay et al. (1) presented data demonstrating that
these patients not only have symptomatic improvement with
CRT but may demonstrate greater improvement than
patients with an intrinsic interventricular conduction delay
because of the potential deleterious effects of pacing from
the right ventricular apex.
A prospective trial demonstrated that patients with
chronic atrial fibrillation receive benefits from CRT similar
to those of patients in normal sinus rhythm (2). This further
supports the available data from the Multisite Stimulation
in Cardiomyopathy (MUSTIC)-Atrial Fibrillation trial.
The assessment of interventricular dyssynchrony by
pulsed wave tissue Doppler imaging and strain gauge
techniques were shown to have potential for better deter-
mining patient selection for CRT, for assisting in position-
ing the coronary venous lead, and for subsequently optimiz-
ing the left ventricular to right ventricular timing differences
(3–5).
Cardiac resynchronization therapy implant techniques,
both epicardial lead placement (6) and coronary venous lead
placement, continue to evolve. Worley et al. (7) reported on
a group of 35 patients in whom they performed coronary
venous angioplasty that subsequently allowed successful lead
placement in 70% of the group who might otherwise have
required epicardial lead placement.
Information also emerged about inflammatory markers
and neurohumoral changes after CRT. Cardiac resynchro-
nization therapy was shown to lower levels of brain natri-
uretic peptide, atrial natriuretic peptide, and endothelin-1
(8), and Theodorakis et al. (9) demonstrated lower
interleukin-6 values with CRT.
Many clinicians are struggling with the implications of
the Multicenter Automatic Defibrillator Implantation
Trial-II (MADIT-II) and how to apply these data to the
large population of patients who meet these criteria. As of
mid-2003, there is no ruling from the Centers for Medicare
and Medicaid Services, that is, MADIT-II criteria do not
represent a reimbursed criterion. Sharma et al. (10) assessed
all their patients who would meet MADIT-II criteria and
found that if applied nationally, this would lead to addi-
tional implants in approximately 460,000 patients. Other
investigators found that MADIT-II results can be general-
ized to tertiary referral centers (11), and others demon-
strated that adding bundle-branch block to the MADIT-II
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criteria further defined patients who are at even higher risk
for sudden cardiac death (12).
Numerous investigations supported the use of atrial
pacing algorithms in permanent pacemakers which will
detect and alter pacing rates in the presence of premature
atrial contractions (13–15). This is an area in which data are
expanding rapidly, with multiple trials assessing the use of
atrial pacing algorithms in patients with a history of par-
oxysmal atrial tachyarrhythmias or who are at risk for the
development of atrial tachyarrhythmias.
Several randomized clinical trials have assessed the effect
of pacing mode on morbidity and mortality, that is, VVI or
VVIR versus physiologic (DDD, DDDR, AAI, AAIR)
pacing modes. Initial results from the United Kingdom-
Pacing And Cardiovascular Events (UK-PACE) trial were
presented. This trial compared DDD with VVI and VVIR
modes and included patients who were older than 70 years
and had atrioventricular block. In UK-PACE, the primary
end point was all-cause mortality, and the combined sec-
ondary end point was cardiac death, atrial fibrillation, heart
failure, hospitalization, stroke, thromboembolic event, or
reoperation.
There was no significant difference in mortality and no
significant difference in the incidence of atrial fibrillation.
Relatively consistently, previous trials had demonstrated a
decrease in atrial fibrillation with physiologic pacing modes,
with one exception.
There was no difference in the UK-PACE composite end
point between DDD and VVI/VVIR pacing modes.
The mechanisms and management of atrial fibrillation
are still of substantial interest. A randomized clinical trial
compared oral amiodarone with placebo from two weeks
before to eight weeks after cardioversion (16). Amiodarone
was shown to have the advantage of chemical cardioversion
in a significant number of patients, but pretreatment did not
alter the efficacy of cardioversion. The recurrence rate of
atrial fibrillation after a first relapse after treatment with
metoprolol, sotalol, or amiodarone was also reported (17).
The study demonstrated a better outcome with metoprolol,
with 40% of patients remaining free of symptomatic recur-
rence of atrial fibrillation, and better compliance.
Results from the Percutaneous Left Atrial Appendage
Transcatheter Occlusion (PLAATO) feasibility trial were
presented (18). It included 56 patients and demonstrated
that the device for percutaneous left atrial appendage
transcatheter occlusion is safe and effective. Whether this
confers long-term protection from stroke will be determined
by long-term follow-up and by a larger trial.
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